|Bid||0.00 x 1100|
|Ask||148.50 x 1100|
|Day's Range||135.25 - 137.82|
|52 Week Range||100.20 - 143.22|
|PE Ratio (TTM)||52.33|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Medtronic Plc topped analysts' estimates for profit in the fourth quarter as it kept a tight lid on costs and upped sales of its heart valves and insulin pumps, offsetting the impact of hurricane damage to production in Puerto Rico. "Relative to nervousness that investors have come to expect around Medtronic's earnings releases, we thought the fourth-quarter print was solid," Evercore ISI analyst Vijay Kumar said. Sales across Medtronic's business units beat analysts' estimates, according to Thomson Reuters I/B/E/S, and the company forecast an adjusted profit of $5.10 to $5.15 per share for fiscal 2019 compared to expectations of $5.14.
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The NeuroPace Responsive Neurostimulation System “literally provides peace of mind I never imagined could exist,” she said. Armed with the knowledge of what worked before, the system instructs the implant to stimulate users’ brains to interrupt a seizure at its onset. The innovation is part of a larger phenomenon that has big implications for how we identify and treat disease: the introduction of artificial intelligence to consumer and clinical electronics.
On May 3, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 19.2x, while its PE ratio was 55.7x. This compares to the company’s forward PE and LTM (last-12-months) PE multiples of 20.1x and 57.6x, respectively, in April.
(Continued from Prior Part)ABT’s Medical Device business In 1Q18, Abbott Laboratories (ABT) registered sales of $7.4 billion, representing YoY (year-over-year) growth of ~16.7%. The company’s Medical Device segment registered strong growth and contributed ~37.0% to the company’s total sales, the highest of all four of its segments. ABT’s Medical Device segment sales came in at ~$2.7 billion in 1Q18. On a reported basis, the segment’s sales growth was ~14.6% on a YoY basis. However, on an organic basis, the segment’s sales increased ~9.4%. ...
On April 18, Abbott Laboratories (ABT) released its 1Q18 earnings results. The company registered revenues of $7.4 billion, which represents YoY (year-over-year) growth of ~16.7%. These sales results exceeded analysts’ estimates.
On May 2, Abbott Laboratories (ABT) ended trading at a closing price of $58.14 per share. Currently, the stock is trading lower than its 50-day moving average of $59.91 and near its 200-day moving average of $58.22.
Abbott Laboratories (ABT) reported its 1Q18 results on April 18. Let’s look at Wall Street analysts’ recommendations for ABT stock after its earnings release. On May 2, a Reuters survey noted that 20 brokerage firms were tracking ABT. Of these firms, 16 analysts recommended a “buy” or “strong buy.” The rest of the firms gave a “hold” rating on the stock. None of the firms gave a “sell” recommendation for Abbott Laboratories.
Capital One Financial • COF-NYSE Underperform • Price $97.42 on April 24 by Evercore ISI The bank holding company, which focuses on credit cards, auto loans, savings, and other accounts reported first-quarter 2018 earnings per share from continuing operations of $2.61. Setting aside its restructuring charges and securities gains, we peg core earnings at $2.63, versus our estimate of $2.40 and the consensus estimate of $2.33. Overall, it was a relatively solid quarter, marked by better deposit growth, slightly better loans/receivables growth, and higher interchange fees.
Stocks that moved substantially or traded heavily Wednesday: Comcast Corp., up 91 cents to $34.26 The cable company had a solid first quarter and offered to buy U.K. broadcaster Sky for $30 billion. Texas ...
Motivated by a goal to create meaning in his work, Edwards Lifesciences[ticker symb=EW] CEO Mike Mussallem pushed boundaries to follow his passion for helping people live their best lives. In the process, Mussallem and his team have transformed Edwards into the global leader in patient-focused innovations for structural heart disease, as well as critical care and surgical monitoring. Mussallem believes...
Premarket trading turned mixed on Wednesday as Boeing, Twitter and Cree gained, Alphabet got an upgrade and Comcast bid $31 billion for Britain's Sky.
Japan is the company’s highest growth region outside the United States. Therapy adoption continues to be the major factor driving Edwards’ THVT segment sales in 1Q18. For more on related developments, read Recent Developments at Edwards Lifesciences.
Edwards Lifesciences Corp (NYSE:EW) and Illumina, Inc. (NASDAQ:ILMN) reported their quarterly earnings results after hours Tuesday, while Tesla Inc (NASDAQ:TSLA) finds itself in hot waters over a contract dispute. Edward Lifesciences reported its latest quarterly results after hours yesterday. The company announced that the first-quarter global sales of its heart valves, a metric that marks the company’s most important growth driver, increased 2.3% year-over-year to $551.5 million.
Edwards Lifesciences Corp's first-quarter sales for transcatheter heart valves missed Wall Street targets on Tuesday, as the medical device maker lost market share in Europe to its rival, Medtronic Plc. The company's shares fell as much as 8.1 percent in after-market trading as sales of its premium non-invasive device, used to replace diseased aortic valves without open-heart surgery, is its biggest growth driver. "Procedure growth in Europe was double digits this quarter, while our growth was lower due to a year-over-year shift in share to our largest competitor," Chief Executive Officer Michael A. Mussallem said on a call with analysts.
Edwards Lifesciences Corp. shares dropped in late trading Tuesday after the company provided a disappointing forecast. The company reported first-quarter earnings of 96 cents a share on sales of $894.8 ...
Here’s a list of all the top-rated growth stocks that have just been added to the IBD 50, IBD Big Cap 20, Sector Leaders, Stock Spotlight and IPO leaders.
For the first quarter, Edwards reported $937.5 million in adjusted sales and adjusted profit of $1.22 per share.